Understanding therapeutic equivalence in epilepsy

CNS Spectrums

Volumn 15, Issue 2, 2010, Pages 112-123

  Sankar, Raman ^a   Glauser, Tracy A ^b   Bainbridge, Jacquelyn ^c   Benbadis, Selim R ^c   Faught Jr , Raymond E ^c   Gilliam, Frank ^c   Gruenthal, Michael ^c   Hershkowitz, Laura L ^c   Holmes, Gregory L ^c   Husain, Aatif M ^c   Labiner, David M ^c   Montouris, Georgia ^c   Naritoku, Dean K ^c   Olson, Barbara J ^c   Pellock, John M ^c   Penovich, Patricia E ^c   Ramsay, R Eugene ^c   Rho, Jong M ^c   Richards, Karen C ^c   Rosenfeld, William E ^c   Slater, Jeremy D ^c   Smith, Michael C ^c   Spitz, Mark C ^c   Stern, John M ^c   Vossler, David G ^c   Wheless, James W ^c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FOSPHENYTOIN SODIUM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; DRUG SOLUBILITY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; MEDICAL SOCIETY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEIZURE; TREATMENT OUTCOME;

EID: 77949284499     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900027358     Document Type: Review

References (57)

1. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15:165-176.
2. Feely M, Crawford P, Kramer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur J Hosp Pharm Sci. 2005;11:83-87.
3. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007;6:465-468.
4. Zachry WM III, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia. 2009;50(3):493-500.
5. US Food and Drug Administration. History of the FDA. http://www.fda.gov/ AboutFDA/WhatWeDo/History/default.htm. Accessed January 20, 2010.
6. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25:1578-1592.
7. Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci. 2000;27:37-43.
8. Welage LS, Kirking DM, Ascione FJ, Gaither CA. Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc (Wash). 2001;41:856-867.
9. US Food and Drug Administration Center for Drug Evaluation and Research. Approved Drug Products With Therapeutic Equivalence Evaluations. 27th ed. Rockville, MD: US Department of Health and Human Services; 2007.
10. Berg MJ. What's the problem with generic antiepileptic drugs? A call to action. Neurology. 2007;68:1245-1246.
11. Nuwer MR, Browne TR, Dodson WE, et al. Generic substitutions for antiepileptic drugs. Neurology. 1990;40:1647-1651.
12. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf. 2000;23:173-182.
13. Dilantin Kapseals [package insert]. New York, NY: Parke-Davis; 2009.
14. Tegretol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009.
15. Topamax [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009.
16. Depakote ER Tablets [package insert]. North Chicago, IL: Abbott Laboratories; 2009.
17. Neurontin [package insert]. New York, NY: Parke-Davis; 2009.
18. Lamictal [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
19. Varia SA, Schuller S, Stella VJ. Phenytoin prodrugs IV: hydrolysis of various 3-(hydroxymethyl) phenytoin esters. J Pharm Sci. 1984;73:1074-1080.
20. Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987;258:1200-1204.
21. Henney JE. From the Food and Drug Administration: review of generic bioequivalence studies. JAMA. 1999;282(21):1995.
22. Banahan BF, Bonnarens JK. Generic substitution of NTI drugs: issues for formulary committee consideration. Formulary. 1998;33(11):1082-1096.
23. Department of Health and Human Services. Approved Drug Products with Therapeutic Equivalence Evaluations. 27th ed. Cumulative Supplement 12. 2007.
24. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy. Is it safe? Seizure. 1996;5:1-5.
25. Trimble MR. Generic prescribing. Hum Psychopharmacol. 1987;2:1-2.
26. Cassels C. No generic substitution of AEDs without physician and patient consent, says AAN. http://www.medscape.com/viewarticle/555489. Accessed March 25, 2009.
27. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother. 1992;26:775-777.
28. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1990;40:1641-1643.
29. Miller JW, Anderson GD, Doherty MJ, Poolos NP. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action. Neurology. 2007;69:1806-1808.
30. Epilepsy Foundation. Position on Switching of Antiepileptic Drugs. http://www.epilepsyfoundation.org/advocacy/care/genedrev.cfm. Accessed December 11, 2009.
31. Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav. 2002;3:522-525.
32. Berg MJ, Gross RA. Physician and patients perceive that generic drug substitution of anti-epileptic drugs can cause breakthrough seizures-results from a US survey [Abstract]. Epilepsia. 2006;47(suppl 4):155.
33. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology. 2004;63:1494-1496.
34. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology. 1993;43:2696-2697.
35. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 1987;37(12):1885.
36. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004;5:995-998.
37. Haskins LS, Tomaszewski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav. 2005;7:98-105.
38. Kramer GK, Steinhoff BJ, Feucht M, Pfafflin M, May T. Generic antiepileptic drugs: experiences of physicians in Germany, Austria, and Switzerland [Abstract]. Epilepsia. 2006;47(suppl 4):193.
39. Krämer G, Steinhoff BJ, Feucht M, Pfäfflin M, May TW. Experiences with generic drugs in epilepsy patients. Results of an internet-based questionnaire study in Germany, Austria, and Switzerland [in German]. Akt Neurol. 2006;33:431-438.
40. Mayer T, May TW, Altenmüller DM, Sandmann M, Wolf P. Clinical problems with generic antiepileptic drugs: comparison of sustained-release formulations of carbamazepine. Clin Drug Investig. 1999;18:17-26.
41. Makus KG, McCormick J. Substituting generic lamotrigine for brand-name lamotrigine (Lamictal) in patients with epilepsy: an observational assessment of outcomes in Canada. [Abstract]. Epilepsia. 2006;47(suppl 4):194.
42. Makus KG, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther. 2007;29:334-341.
43. Andermann F, Duh MS, Gosselin A, Lefebvre P, Paradis PE. Adverse clinical consequences of compulsory generic switching of antiepileptic drugs [Abstract]. Epilepsia. 2006;47(suppl 4):189.
44. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464-469.
45. Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs. 2004;18:617-628.
46. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia. 2002;43(suppl 4):10-16.
47. State laws or statutes governing generic substitution by pharmacists. http://professionals.epilepsy.com/page/statutes-by-pharmacists.html. Accessed March 25, 2009.
48. Tennessee Code Annotated, Title 53, Chapter 10, Part 2; section 53-10-210. Pharmacy, Pharmacists - Requires notification before interchanging or substituting for a prescribed anti-epileptic drug in certain situations. Amendment No. 2 to HB0121.
49. Tennessee Code Annotated, Title 53, Chapter 10, Part 2; section 53-10-204. Substitution authorized - Instructions of prescriber.
50. Tennessee Code Annotated, Title 53, Chapter 10, Part 2; section 53-10-205. Least expensive generic equivalent if authorized by prescriber.
51. American Pharmaceutical Association. Substitution of critical dose drugs: issues, analysis, and decision making. http://www.pharmacist.com/AM/Template. cfm?Section=Home2&CONTENTID=14423&TEMPLATE=/CM/ContentDisplay.cfm. Accessed March 25, 2009.
52. National Institute for Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20. National Collaborating Center for Primary Care. October 2004. http://www.nice.org.uk/guidance/index.jsp?action= byID&o=10954. Accessed March 25, 2009.
53. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults: a national clinical guideline. Edinburgh, Scotland: Royal College of Physicians, April 2003. http://www.sign.ac.uk/guidelines/fulltext/70/ index.html. Accessed March 25, 2009.
54. British Epilepsy Association. Epilepsy Action position statements: Consistency of Supply. http://www.epilepsy.org.uk/about/positionstatements/ consistency.html. Accessed March 25, 2009.
55. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian League Against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006;47(suppl 5):16-20.
56. Generics -- equal or not? Aust Prescriber. 2003;26:124-125.
57. American Epilepsy Society. The substitution of different formulations of antiepileptic drugs for the treatment of epilepsy. Position statement November 29, 2007. http://www.aesnet.org/index.cfm?objectid=77B10758-E7FF-0F41- 2C82BE234AB8CD24. Accessed December 4, 2009.